Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells
暂无分享,去创建一个
Xiaoping Zhou | Li Zhao | Shaoli Song | Xiaoguang Sun | Gang Huang | Jianju Liu | Ping Miao | Liu Liu | Hao Yang | Xiaoping Zhao | Hui Yan | Wenzhi Jia | Jiajin Li
[1] X. Zhao,et al. p54nrb/NONO regulates lipid metabolism and breast cancer growth through SREBP-1A , 2016, Oncogene.
[2] G. Huang,et al. Arginine Methylation of SREBP1a via PRMT5 Promotes De Novo Lipogenesis and Tumor Growth. , 2016, Cancer research.
[3] Xiaoping Zhou,et al. Dichloroacetate restores drug sensitivity in paclitaxel-resistant cells by inducing citric acid accumulation , 2015, Molecular Cancer.
[4] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[5] O. Topolcan,et al. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation , 2015, Tumor Biology.
[6] Xiaoping Zhou,et al. Inhibition of Lipolysis by Mercaptoacetate and Etomoxir Specifically Sensitize Drug-Resistant Lung Adenocarcinoma Cell to Paclitaxel , 2013, PloS one.
[7] M. Tan,et al. Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.
[8] Jie Zhou,et al. Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis , 2012, Cell cycle.
[9] H. Zhang,et al. MARVELD1 inhibited cell proliferation and enhance chemosensitivity via increasing expression of p53 and p16 in hepatocellular carcinoma , 2012, Cancer science.
[10] Timothy F. Osborne,et al. SREBPs: metabolic integrators in physiology and metabolism , 2012, Trends in Endocrinology & Metabolism.
[11] M. V. Heiden,et al. Targeting cancer metabolism: a therapeutic window opens , 2011, Nature Reviews Drug Discovery.
[12] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[13] Bo-Liang Li,et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. , 2011, Cell metabolism.
[14] K. D. Kikawa,et al. Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association. , 2010, Carcinogenesis.
[15] P. Harari,et al. Understanding resistance to EGFR inhibitors—impact on future treatment strategies , 2010, Nature Reviews Clinical Oncology.
[16] Ziwei Gu,et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. , 2009, Chemistry & biology.
[17] L. Cantley,et al. PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.
[18] Xianlin Han,et al. Epidermal Growth Factor Receptors Are Localized to Lipid Rafts That Contain a Balance of Inner and Outer Leaflet Lipids , 2005, Journal of Biological Chemistry.
[19] Christopher M. Adams,et al. Cholesterol and 25-Hydroxycholesterol Inhibit Activation of SREBPs by Different Mechanisms, Both Involving SCAP and Insigs* , 2004, Journal of Biological Chemistry.
[20] M. Gleave,et al. Dysregulation of Sterol Response Element-Binding Proteins and Downstream Effectors in Prostate Cancer during Progression to Androgen Independence , 2004, Cancer Research.
[21] K. Mikami,et al. Membrane fluidity and the perception of environmental signals in cyanobacteria and plants. , 2003, Progress in lipid research.
[22] G. Ge,et al. Effect of membrane fluidity on tyrosine kinase activity of reconstituted epidermal growth factor receptor. , 2001, Biochemical and biophysical research communications.
[23] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[24] B. Maresca,et al. Does the membrane's physical state control the expression of heat shock and other genes? , 1998, Trends in biochemical sciences.